GLP Analogs Market Report 2025 (Global Edition)

Global GLP Analogs Market Report 2024 Market Size Split by Drug (Exenatide, Liraglutide, Lixisenatide, Dulaglutide, Semaglutide, Albiglutide), by Distribution Channel (Retail Pharmacy, Hospital Pharma...

GLP Analogs Market Report Description

We have various report editions of GLP Analogs Market, hence please contact our sales team and author directly to obtain/purchase a desired Edition eg, Global Edition, Regional Edition, Country Specific Report Edition, Company Profiles, Forecast Edition, etc. Request for your Free Sample PDF/Online Access.

Competitive Landscape of the GLP Analogs Market

Key players deploy strategic initiatives such as product innovations, partnerships, and mergers. Companies prioritize R&D to introduce cutting-edge reagents, ensuring a competitive edge. Robust distribution networks and adherence to quality standards amplify market presence, fostering an environment where agility and innovation define industry leaders.

GLP Analogs Industry News

In January 2024, Sciwind Biosciences Co., Ltd. reported positive interim Phase 1 results for oral ecnoglutide (XW004), a long-acting GLP-1 analog for the treatment of type 2 diabetes and obesity. XW004 is an oral tablet formulation. 

(Source: https://www.prnewswire.com/news-releases/sciwind-biosciences-announces-positive-results-from-phase-1-clinical-trial-of-xw004-an-oral-formulation-of-long-acting-glp-1-analog-ecnoglutide-302042633.html)

In November 2023, AstraZeneca and Eccogene signed an exclusive license agreement for ECC5004, an investigational oral once-daily glucagon-like peptide one receptor agonist (GLP-1RA) intended for treating obesity, type-2 diabetes, and other cardiometabolic conditions.

(Source: https://www.astrazeneca.com/media-centre/press-releases/2023/agreement-with-eccogene-for-clinical-stage-glp-1ra.html)

Top Companies Market Share in GLP Analogs Industry: (In no particular order of Rank)

• Novo Nordisk
• AstraZeneca
• Eli Lily
• GSK
• Sanofi
• Bristol-Myers Squibb
• Amylin
• Confidential Data
• Access The Paid Version
• Data Hidden

*List of Second Tier Companies, List of Third Tier/ Start-up Companies (Inquire with sales executive) Request Any Company Profile for Preview Purpose OR Data Validation!

If any Company(ies) of your interest has/have not been disclosed in the above list then please let us know the same so that we will check the data availability in our database and provide you the confirmation or include it in the final deliverables.

Regional Analysis of the GLP Analogs Market

Which Region will dominate the GLP Analogs Market in 2024?

According to Cognitive Market Research, North America dominated the market in 2024 and accounted for around 40% of the global revenue. The region's dominance was attributed to the high prevalence of diabetes and obesity, well-established healthcare infrastructure, and strong pharmaceutical research and development capabilities. Additionally, favorable reimbursement policies and increasing adoption of advanced therapeutics further boosted market growth in North America. The presence of key market players and ongoing technological advancements also contributed to the region's major share in the GLP analog market.

Which Region is Expanding at the Fastest CAGR?

Asia Pacific is the fastest-growing region in the GLP analogs market, driven by the rising prevalence of diabetes and obesity and increasing healthcare expenditure. Additionally, initiatives to improve access to advanced healthcare technologies and the presence of a large patient pool contribute to market expansion. Moreover, collaborations between pharmaceutical companies and regional healthcare providers to develop and commercialize novel GLP analog therapies further accelerate market growth in the Asia Pacific.

The current report Scope analyzes GLP Analogs Market on 5 major region Split (In case you wish to acquire a specific region edition (more granular data) or any country Edition data then please write us on info@cognitivemarketresearch.com

• North America (United States, Canada, Mexico)
• Europe (United Kingdom, France, Germany, Italy, Russia, Spain, Sweden, Denmark, Netherlands, Switzerland, Belgium)
• Asia-Pacific (China, Japan, Korea, India, Australia, Philippines, Singapore, Malaysia, Thailand, Indonesia, Rest of APAC)
• South America (Brazil, Argentina, Colombia, Peru, Chile, Rest of South America)
• Middle East and Africa (Saudi Arabia, Turkey, Nigeria, UAE, Egypt, South Africa, GCC Countries, Rest of MEA)

The above graph is for illustrative purposes only.

North America GLP Analogs Market

According to Cognitive Market Research, the global GLP analogs market size was estimated at USD 5,451.2 Million, out of which North America held the major market of more than 40% of the global revenue with a market size of USD 2180.48 million in 2024 and will grow at a compound annual growth rate (CAGR) of 2.7% from 2024 to 2031. North America was the largest region in the GLP (Glucagon-like peptide) analogs market, boasting a significant market share. Factors such as the high prevalence of diabetes and obesity, advanced healthcare infrastructure, and strong investment in research and development contributed to the region's dominance. Moreover, key market players and favorable regulatory frameworks further propelled market growth in North America. Additionally, increasing awareness among healthcare professionals and patients about the benefits of GLP analogs played a crucial role in driving demand for these therapies across the region.

• According to Cognitive Market Research, the US had a major share in the GLP analogs market with a market size of USD 1,720.40 million in 2024 and is projected to grow at a CAGR of 2.5% during the forecast period. With its advanced healthcare infrastructure, high prevalence of diabetes, and robust pharmaceutical industry, the US emerged as a major contributor to the growth of the GLP analog market. 
• The Canada GLP analogs market had a market share of USD 261.66 million in 2024 and is projected to grow at a CAGR of 3.5% during the forecast period. In Canada, the GLP analogs market witnessed significant growth, propelled by rising awareness of diabetes and obesity.
• The Mexico GLP analogs market is projected to grow at a CAGR of 3.2% during the forecast period, reaching a market size of USD 198.42 million in 2024.

Europe GLP Analogs Market

Cognitive Market Research shows a market value of USD 5,451.2 million in 2024 and is projected to expand at a compound annual growth rate (CAGR) of 3.0% from 2024 to 2031. Europe accounted for a share of over 30% of the global market size of USD 1,635.36 million. This expansion was propelled by rising awareness of metabolic disorders, including diabetes and obesity, advancements in healthcare infrastructure, and favorable reimbursement policies. Additionally, increased regional research and development activities contributed to introducing innovative GLP analog formulations and treatment modalities. The growing prevalence of diabetes and obesity, particularly in European countries, drove the demand for these therapies, fostering market expansion and creating opportunities for manufacturers and healthcare providers to address the unmet medical needs of patients with metabolic conditions.

• The United Kingdom GLP analogs market had a market share of USD 274.74 million in 2024 and is projected to grow at a CAGR of 3.8% during the forecast period. The market grew significantly due to the rising prevalence of diabetes and obesity, technological advancements in drug delivery, increased awareness, favorable reimbursement policies, and expanding research activities. 
• The France GLP analogs market is projected to grow at a CAGR of 2.2% during the forecast period, with a market size of USD 150.45 million in 2024.
• According to Cognitive Market Research, the Germany GLP analogs market size was valued at USD 323.80 million in 2024 and is projected to grow at a CAGR of 3.2% during the forecast period. Germany experienced a surge in demand for GLP analogs, reflecting increasing awareness and adoption of these therapies for managing diabetes and obesity. 
• The Italy GLP analogs market is projected to grow at a CAGR of 2.4% during the forecast period, with a market size of USD 140.64 million in 2024.
• The Russian GLP analogs market is projected to grow at a CAGR of 2.0% during the forecast period, with a market size of USD 253.48 million in 2024.
• The Spain GLP analogs market is projected to grow at a CAGR of 2.1% during the forecast period, reaching USD 134.10 million in 2024.
• The Luxembourg GLP analogs market is projected to grow at a CAGR of 3.1% during the forecast period, reaching a market size of USD 50.70 million in 2024.
• The Portugal GLP analogs market is projected to grow at a CAGR of 2.8% during the forecast period, with a market size of USD 34.34 million in 2024.
• The Greece GLP analogs market is projected to grow at a CAGR of 3.3% during the forecast period, with a market size of USD 19.62 million in 2024.
• The rest of Europe's GLP analogs market is projected to grow at a CAGR of 1.7% during the forecast period, reaching a market size of USD 253.48 million in 2024.

Asia Pacific GLP Analogs Market

According to Cognitive Market Research, the global GLP analogs market size was estimated at USD 5,451.2 Million, out of which Asia Pacific held the market of around 23% of the global revenue with a market size of USD 1253.38 million in 2024 and will grow at a compound annual growth rate (CAGR) of 6.5% from 2024 to 2031. With a rising prevalence of diabetes and obesity coupled with increasing healthcare expenditure and improving healthcare infrastructure, the region witnessed significant market expansion. Moreover, initiatives to enhance awareness about metabolic disorders and advancements in healthcare technologies further fueled the demand for GLP analogs in the Asia Pacific region. Additionally, strategic collaborations and partnerships among pharmaceutical companies to expand their presence in emerging markets contributed to the accelerated growth of the GLP analogs market in the Asia Pacific.

• According to Cognitive Market Research, the China GLP analogs market was valued at USD 564.20 million in 2024 and is projected to grow at a CAGR of 6.0% during the forecast period. China held a significant portion of the GLP analogs market, driven by the country's increasing prevalence of diabetes and obesity, which contributed to its major share.
• The Japan GLP analogs market is projected to witness growth at a CAGR of 5.0% during the forecast period, with a market size of USD 173.02 million in 2024.
• The India GLP analogs market had a market share of USD 150.45 million in 2024 and is projected to grow at a CAGR of 8.3% during the forecast period. India experienced rapid growth in the GLP analogs market due to increasing diabetes prevalence, rising awareness, improved healthcare infrastructure, and expanding access to innovative therapies.
• The South Korea GLP analogs market is projected to grow at a CAGR of 5.6% during the forecast period, reaching a market size of USD 125.38 million in 2024.
• The Australian GLP analogs market is projected to grow at a CAGR of 6.2% during the forecast period, with a market size of USD 65.20 million in 2024.
• The South East Asia GLP analogs market is projected to grow at a CAGR of 7.5% during the forecast period, with a market size of USD 86.51 million in 2024.
• The Rest of the Asia Pacific GLP analogs market is projected to grow at a CAGR of 6.3% during the forecast period, reaching a market size of USD 89.02 million in 2024.

 

South America GLP Analogs Market

According to Cognitive Market Research, the global GLP analogs market size was estimated at USD 5,451.2 Million, of which the Latin American market has more than 5% of the global revenue with a market size of USD 272.56 million in 2024. It will grow at a compound annual growth rate (CAGR) of 3.9% from 2024 to 2031. Factors such as the increasing prevalence of diabetes and obesity, rising awareness about metabolic disorders, and improving healthcare infrastructure contributed to the region’s expansion—additionally, advancements in drug delivery systems and new GLP analog formulations enhanced treatment options for regional patients. Despite economic challenges and healthcare disparities, Latin America showcased significant potential for market development, attracting investments from pharmaceutical companies aiming to address the unmet medical needs of the population affected by metabolic diseases.

• According to Cognitive Market Research, the Brazil GLP analogs market size was valued at USD 116.66 million in 2024 and is projected to grow at a CAGR of 4.5% during the forecast period. Brazil secured a larger share in the GLP analogs market due to the increasing prevalence of diabetes and obesity, driving demand for effective therapies.
• The Argentina GLP analogs market had a market share of USD 45.79 million in 2024 and is projected to grow at a CAGR of 4.8% during the forecast period. Argentina experienced notable growth in the GLP analogs market, driven by the increasing prevalence of diabetes and obesity and the rising adoption of advanced treatment options.
• The Colombia GLP analogs market is projected to grow at a CAGR of 3.7% during the forecast period, reaching a market size of USD 24.26 million in 2024.
• The Peru GLP analogs market is projected to grow at a CAGR of 4.1% during the forecast period, reaching a market size of USD 22.35 million in 2024.
• The Chile GLP analogs market is projected to grow at a CAGR of 4.2% during the forecast period, with a market size of USD 19.62 million in 2024.
• The Rest of the Latin America GLP analogs market is projected to grow at a CAGR of 3.0% during the forecast period and reach a market size of USD 43.88 million in 2024.

Middle East and Africa GLP Analogs Market

According to Cognitive Market Research, the global GLP analogs market size was estimated at USD 5,451.2 Million, out of which the Middle East and Africa held the major market of around 2% of the global revenue with a market size of USD 109.02 million in 2024 and will grow at a compound annual growth rate (CAGR) of 4.2% from 2024 to 2031. Factors such as the increasing prevalence of diabetes and obesity and rising awareness about the benefits of GLP analogs drive market expansion in the region. Additionally, investments in healthcare infrastructure and advancements in drug delivery technologies contributed to market growth. Despite challenges such as limited access to healthcare services in certain areas, the region's evolving healthcare landscape and efforts to combat metabolic disorders fostered a conducive environment for adopting GLP analog therapies, paving the way for continued growth in the market.

• According to Cognitive Market Research, the GCC Countries GLP analogs market size was valued at USD 46.66 million in 2024 and is projected to grow at a CAGR of 5.0% during the forecast period. GCC countries held a significant portion of the market share in the GLP analogs market due to rising diabetes prevalence.
• The Egypt GLP analogs market is projected to grow at a CAGR of 4.5% during the forecast period, reaching a market size of USD 11.45 million in 2024.
• The South African GLP analogs market is projected to grow at a CAGR of 5.2% during the forecast period, reaching USD 17.23 million in 2024. South Africa experienced rapid growth in its GLP analogs Market due to increased diabetes prevalence and improved healthcare infrastructure.
• The Turkey GLP analogs market is projected to grow at a CAGR of 3.7% during the forecast period, reaching a market size of USD 9.38 million in 2024.
• The Nigeria GLP analogs market is projected to grow at a CAGR of 3.3% during the forecast period, reaching a market size of USD 11.45 million in 2024.
• The Rest of the MEA GLP analogs market is projected to grow at a CAGR of 3.2% during the forecast period, reaching a market size of USD 12.86 million in 2024

 

GLP Analogs Market Analysis

GLP Analogs Drug Segment Analysis

According to Cognitive Market Research, exenatide held the major market share over the forecast period. Exenatide, a well-established GLP-1 receptor agonist, is widely utilized in managing type 2 diabetes. Its popularity stems from its efficacy in improving glycemic control, promoting weight loss, and reducing the risk of cardiovascular events. With its proven therapeutic benefits and increasing adoption by healthcare professionals, the exenatide segment continues to dominate the market, contributing substantially to overall market revenue.

The dulaglutide segment emerged as the fastest-growing segment in the GLP analogs market. Dulaglutide, a long-acting GLP-1 receptor agonist administered once weekly, gained traction due to its convenience and efficacy in managing type 2 diabetes and obesity. Its sustained release mechanism provides continuous blood sugar control, reducing the frequency of injections and improving patient adherence. These factors contributed to the rapid expansion of the dulaglutide segment within the GLP analogs market.

• Exenatide
• Liraglutide
• Lixisenatide
• Dulaglutide
• Semaglutide
• Albiglutide

The above Chart is for representative purposes and does not depict actual sale statistics. Access/Request the quantitative data to understand the trends and dominating segment of GLP Analogs Industry. Request a Free Sample PDF!

GLP Analogs Distribution Channel Segment Analysis

According to Cognitive Market Research, the hospital pharmacy segment held a significant share of the GLP Analogs Market, driven by the widespread adoption of GLP analogs for diabetes management within hospital settings. Hospitals are primary centers for diabetes treatment and care, and they play a crucial role in dispensing and administering these medications to patients. Hospitals often have specialized diabetes clinics and endocrinology departments that contribute to the substantial usage of GLP analogs, further solidifying the segment's major share in the market.

The retail pharmacy segment emerged as the fastest-growing sector in the GLP analogs market. This growth is attributed to increased consumer accessibility and convenience, with retail pharmacies offering a wide range of GLP analogs to patients managing diabetes and obesity. Moreover, the expansion of retail pharmacy chains and online platforms has further facilitated the distribution and availability of these medications, driving market penetration and contributing significantly to overall market growth.

• Retail Pharmacy
• Hospital Pharmacy

The above Graph is for representation purposes only. This chart does not depict actual Market share.

Author's Detail

Manjiri Kanhere

Senior Research Associate at Cognitive Market Research

LinkedIn

Profile

Manjiri Kanhere is an experienced market researcher focused on the Pharma & Healthcare industry. With over 3+ years of experience, She has worked with major pharmaceutical companies and healthcare providers, helping them to understand market trends, identify new business opportunities, and develop effective sales & marketing strategies. Her expertise lies in the ability to analyze complex data sets and deliver insights that drive business decisions. At Cognitive Market Research, she handles the market research related to Pharma and healthcare industry.

Author's Conclusion